Aerolized antibiotics for the treatment of ventilator associated pneumonia: A new era!

George T. Dimopoulos, Marin Kollef, Dimitrios K. Matthaiou, Bruce Montgomery

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


The increasing rate of ventilator-associated pneumonia (VAP) caused by multidrug-resistant pathogens warrants the development of new treatment strategies. Carefully engineered delivery systems are undergoing evaluation to test the hypothesis that aerosolized administration of antibiotics will provide high local concentrations and fast clearance, which in turn may improve efficacy and decrease the risk of microbial resistance. Recent studies indicate that aerosolized delivery systems for specially formulated antibiotics yield high local concentrations with rapid clearance and low systemic exposure. Preliminary clinical studies reveal that aerosolized delivery of antibiotics is well tolerated and active, when combined with intravenous antibiotics. No single aerosolized antibiotic is likely to provide broad-spectrum activity against both Gram-negative and Gram-positive bacteria. Large multicenter trials are needed to determine whether preliminary findings will translate to improved clinical activity and decreased microbial resistance in VAP patients, and to optimize the use of aerosolized antibiotics.

Original languageEnglish
Pages (from-to)87-93
Number of pages7
Issue number1
StatePublished - Mar 2014


  • Aerosolized antibiotics
  • Pharmacokinetics
  • Ventilator-associated pneumonia


Dive into the research topics of 'Aerolized antibiotics for the treatment of ventilator associated pneumonia: A new era!'. Together they form a unique fingerprint.

Cite this